• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名新冠肺炎患者的鼻眶毛霉菌病:一项严峻挑战。

Rhino-Orbital Mucormycosis in a COVID-19 Patient: A Dreadful Challenge.

作者信息

Dhakal A, Pokharel M, Madhup S, Khadka L, Sapkota B

机构信息

Department of ENT-HNS, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal.

出版信息

Kathmandu Univ Med J (KUMJ). 2022 Apr-Jun;20(78):249-251.

PMID:37017177
Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). COVID-19 infections may be associated with a wide range of bacterial and fungal co-infections. Recent studies are reporting invasive fungal infection associated with severe COVID-19. Herein, we report a case of COVID-19 rhino-orbital mucormycosis infection caused by Rhizopus sps in a 32 year old diabetic patient who was successfully managed with early aggressive debridement of infected tissue endoscopically with extended ethmoidectomy by modified Denker's approach along with orbital decompression and antifungal therapy with Liposomal Amphotericin B and Posaconazole. Serial diagnostic nasal endoscopy showed no evidence of progression of the infection. The patient was discharged on 21st day of hospitalization still on oral Posaconazole for a total of 3 months.

摘要

2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的一种大流行性疾病。COVID-19感染可能与多种细菌和真菌合并感染有关。最近的研究报告了与严重COVID-19相关的侵袭性真菌感染。在此,我们报告一例由根霉属引起的COVID-19鼻眶毛霉菌病感染病例,该患者为一名32岁的糖尿病患者,通过改良Denker法进行扩大筛窦切除术并结合眼眶减压,在内镜下对感染组织进行早期积极清创,同时使用脂质体两性霉素B和泊沙康唑进行抗真菌治疗,成功治愈。系列诊断性鼻内镜检查显示感染无进展迹象。患者在住院第21天出院,仍口服泊沙康唑共3个月。

相似文献

1
Rhino-Orbital Mucormycosis in a COVID-19 Patient: A Dreadful Challenge.一名新冠肺炎患者的鼻眶毛霉菌病:一项严峻挑战。
Kathmandu Univ Med J (KUMJ). 2022 Apr-Jun;20(78):249-251.
2
Rhino-orbito-cerebral mucormycosis caused by Rhizopus microsporus var. microsporus in a diabetic patient with COVID-19.COVID-19 合并糖尿病患者中由微小毛霉变种微小毛霉引起的鼻眶脑毛霉病。
An Bras Dermatol. 2022 Jul-Aug;97(4):501-504. doi: 10.1016/j.abd.2022.02.001. Epub 2022 Jun 9.
3
Rhino-orbital mucormycosis: Our experiences with clinical features and management in a tertiary care center.鼻眶脑型毛霉菌病:我们在一家三级护理中心的临床特征和治疗方面的经验。
Rom J Ophthalmol. 2021 Oct-Dec;65(4):339-353. doi: 10.22336/rjo.2021.69.
4
Is mucormycosis the end? A comprehensive management of orbit in COVID associated rhino-orbital-cerebral mucormycosis: preserving the salvageable.是否意味着毛霉菌病的终结?COVID 相关的鼻-眶-脑毛霉菌病的全面管理:保留可挽救的。
Eur Arch Otorhinolaryngol. 2023 Feb;280(2):819-827. doi: 10.1007/s00405-022-07620-3. Epub 2022 Sep 2.
5
COVID-19 associated rhino-orbital-cerebral mucormycosis-an institutional series.COVID-19 相关的鼻眶脑毛霉菌病——一项机构系列研究。
Ear Nose Throat J. 2024 Jun;103(1_suppl):134S-144S. doi: 10.1177/01455613221077882. Epub 2022 Feb 18.
6
Post-Coronavirus Disease-2019 Rhino-orbital Mucormycosis: A Case Report.新冠肺炎后鼻眶脑毛霉菌病:病例报告。
Nepal J Ophthalmol. 2023 Jul;15(30):108-115. doi: 10.3126/nepjoph.v15i2.46954.
7
Acute Kidney Injury Following Posaconazole for Mucormycosis: SARS-CoV-2 as a Back-Seat Driver.泊沙康唑治疗毛霉菌病后发生急性肾损伤:新型冠状病毒作为幕后推手
Cureus. 2022 Jul 19;14(7):e27018. doi: 10.7759/cureus.27018. eCollection 2022 Jul.
8
Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19.COVID-19 相关的鼻眶脑毛霉菌病继发感染。
Orbit. 2022 Oct;41(5):616-619. doi: 10.1080/01676830.2021.1903044. Epub 2021 Mar 23.
9
Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.COVID 相关毛霉病在肾移植受者中的危险因素和结局。
Transpl Infect Dis. 2022 Apr;24(2):e13777. doi: 10.1111/tid.13777. Epub 2022 Jan 31.
10
Diabetic ketoacidosis and coronavirus disease 2019-associated mucormycosis: a case report.糖尿病酮症酸中毒与 2019 冠状病毒病相关毛霉菌病:病例报告。
J Med Case Rep. 2022 Oct 31;16(1):400. doi: 10.1186/s13256-022-03594-2.